本帖最后由 老马 于 2013-3-13 13:43 编辑 1 E0 l4 t* G# N! H# R' ]+ a0 i
2 U+ e+ s2 k1 k
健择(吉西他滨)+顺铂+阿瓦斯汀0 |+ H$ T( J. f# C- t6 `* c
Gemzar +Cisplatin + Avastin
) A" s/ W$ S$ q! u" bhttp://annonc.oxfordjournals.org/content/21/9/1804.full* V+ U1 y! x- D- s$ p2 b* V1 ^9 _- P7 o
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . V8 [4 J7 w- I+ B( m, f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. : D9 g8 Z0 t5 Q4 j& g
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ G) r' `& |& S9 Q9 c. @0 u2 y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 843)
7 r0 g# z* [" j6 y! x" v
华为网盘附件:
7 W/ v8 x2 \- A【华为网盘】ava.JPG* H3 z, w0 J& y, @* d
|